Innoviva Inc (INVA)
Receivables turnover
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 291,306 | 294,888 | 372,796 | 318,463 | 242,036 |
Receivables | US$ in thousands | 69,621 | 54,672 | 110,711 | 93,931 | 79,427 |
Receivables turnover | 4.18 | 5.39 | 3.37 | 3.39 | 3.05 |
December 31, 2023 calculation
Receivables turnover = Revenue ÷ Receivables
= $291,306K ÷ $69,621K
= 4.18
The receivables turnover for Innoviva Inc has decreased from 35.25 in 2022 to 21.48 in 2023. This indicates that the company's ability to collect payments from customers has decreased in 2023 compared to the previous year. A lower receivables turnover may suggest inefficiencies in the company's credit policies, collection efforts, or possibly issues with customer creditworthiness. Further analysis of the company's accounts receivable management practices and changes in the customer base may be necessary to understand the reasons behind this decline and to identify potential areas for improvement.
Peer comparison
Dec 31, 2023
Company name
Symbol
Receivables turnover
Innoviva Inc
INVA
4.18
Abbott Laboratories
ABT
6.01
AbbVie Inc
ABBV
4.87
Alkermes Plc
ALKS
4.93
Amphastar P
AMPH
5.61
ANI Pharmaceuticals Inc
ANIP
2.80
Arcus Biosciences Inc
RCUS
29.25
Biomarin Pharmaceutical Inc
BMRN
3.75
Bristol-Myers Squibb Company
BMY
4.12
Catalent Inc
CTLT
4.76
Catalyst Pharmaceuticals Inc
CPRX
7.44